Cell therapy company Zhuhai Grit Biotechnology Inc. completed a series A+ financing of undisclosed value to advance its lead tumor-infiltrating lymphocyte (TIL) program, GT-101 for advanced solid tumors, into the clinic by year end while also developing other TIL candidates in its pipeline.

Biopharmas in Asia-Pacific raising money in public or private financings: Adagio, Appili.

While the 441 med-tech financings completed so far this year are nearly as much as this point last year (446), the amount of money raised, at $33.43 billion, is 17% below the amount raised through early August of 2020 ($40.14 billion). Just two months ago, the volume of financings was 10% higher than last year, indicating a recent slowdown in activity. Nevertheless, 2021 appears to be on track to beat the $40.7 billion raised in 2019, and it is already ahead of the full year amounts for 2017 and 2018.

Biopharmas raising money in public or private financings, including: Biocryst, Biorestorative, Blackstone, Creative Medical, Eliem, Eyegate, Harmony, Pharmacyte, Polarisqb, Sydnexis, Visus, Ziopharm Oncology.

Med-tech firms raising money in public or private financings, including: Delcath Systems, Medicortex, Dividend Sweden, S-Alpha Therapeutics, Thermo Fisher Scientific.

Biopharmas raising money in public or private financings, including: Appili, Biovie, Eliem, Navrogen, Sareum, Sierra.